Shukra Pharmaceuticals delivered remarkable financial performance in the June 2026 quarter, with consolidated net profit surging 1158.25% to ₹12.96 crore compared to ₹1.03 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this represents one of the most significant profit growths in the pharmaceutical sector during the quarter.
The company's sales revenue increased by 336.36% to ₹23.52 crore in the quarter ended June 2026, as reported by Business Standard. This substantial revenue growth demonstrates the company's strong market performance and operational efficiency during the quarter.
Operating profit margin (OPM) improved significantly to 81.38% in the June 2026 quarter, compared to 24.49% in the same period last year, according to the company's financial data. This substantial improvement in operational efficiency contributed to the overall strong financial performance.
Profit before tax (PBT) increased by 1226% to ₹18.17 crore in the June 2026 quarter, as reported by Business Standard. Additionally, PBDT (Profit Before Depreciation and Tax) rose by 791% to ₹19.25 crore during the same period, indicating strong operational performance across all key financial metrics.
